Latest Regulatory Milestones News

Australian Silica Quartz Group (ASQ) finalises its acquisition of Australian Kaolin, securing a 47Mt kaolin resource and mining approval for a 250,000 tonne per annum operation. The company progresses kaolin beneficiation in China, explores high purity quartz projects, and advances gold targets at Koolyanobbing, supported by a $1.33m cash position.

Parkway Corporate delivered a record $7.25 million quarterly revenue and $0.54 million EBITDA, powered by a major water infrastructure contract. The company progressed key approvals for its Queensland Brine Management Complex and struck a strategic collaboration with Hitachi to develop advanced brine concentration technology.

Cleo Diagnostics has entered the critical Analytical Validation phase for its ovarian cancer blood test, progressing toward an FDA 510(k) submission targeted for the first half of 2027. The company also secured a U.S. reimbursement pathway to support early market entry post-clearance, backed by a cash balance of A$6.2 million.

PYC Therapeutics has made significant progress across its four RNA therapeutic programs, including dose escalation approvals in its Polycystic Kidney Disease trial and orphan drug designation for its Retinitis Pigmentosa candidate, supported by a robust cash position of $669 million.

Vault Minerals delivered on FY26 gold production guidance with strong quarterly output and cash flow, while progressing key projects and announcing a merger with Genesis Minerals to form a top 20 global gold producer.

NeuroScientific Biopharmaceuticals achieved an 80% clinical response rate in fistulising Crohn’s disease patients treated under the TGA Special Access Scheme, advancing plans for Phase 2 trials and manufacturing scale-up.

Vysarn Limited is set to transform its water services platform with the $60 million acquisition of Welltech, funded by a fully underwritten $65.3 million placement. The deal promises over 37% EPS accretion on a pro forma FY26 basis.

Clinuvel Pharmaceuticals targets year-end for topline results from its pivotal vitiligo trial of SCENESSE® combined with narrowband UVB, aiming to expand the drug's use beyond its current rare disease indication.

Desane Group Holdings progresses key developments in Penrith and Leichhardt, with construction milestones and tenant arrangements set to boost recurring income.

Lumos Diagnostics reported a 6% revenue increase to US$13.2 million for FY26, driven by an 875% surge in FebriDx® sales following a pivotal CLIA waiver. The company expanded U.S. adoption to 170+ healthcare sites and secured milestone payments exceeding US$6 million.

Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.

Syntara secured positive FDA feedback for its Phase 2b amsulostat trial in myelofibrosis and raised $8 million to extend its cash runway to Q3 2027, while preliminary data showed promising brain inflammation reduction in a Parkinson’s-related disorder.